Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.
HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.
A decade-long follow-up of the SECA-II study demonstrates that liver transplantation in highly selected patients with nonresectable colorectal liver-only metastases yields substantial long-term survival and may offer curative potential even
A recent study demonstrates that positive surgical margins in non-small cell lung cancer (NSCLC) do not vary significantly with resection type, supporting selective use of wedge resection without compromising oncologic outcomes.
Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months
This article examines how age, traditionally considered a high-risk factor in lower-grade gliomas, influences prognosis and treatment decisions in the molecular era, highlighting the importance of IDH mutation status.
The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression
A landmark randomized trial demonstrates that multilevel stepped reminders targeting both primary care physicians and patients markedly improve adherence to annual lung cancer screening, while health communication alone may be insufficient
This study analyzes nationwide data from Japan comparing robotic, laparoscopic, and open distal pancreatectomy for malignancy, highlighting robotic surgery’s safety and specific perioperative advantages, notably reduced blood loss and conve
Practical, symptom‑focused recommendations for managing menopause in people with cancer—balancing symptom relief with oncologic safety using nonhormonal first-line strategies, selective use of local estrogen, and shared decision making for
This article explores the unique genomic and transcriptomic features of hepatocellular carcinoma in Fontan-associated liver disease, revealing distinct mutation patterns and poor-prognosis molecular subtypes that inform disease mechanisms a
The TC-MAX is the first validated, disease-specific instrument measuring thyroid cancer-related anxiety, showing strong reliability and validity to inform treatment decisions and improve patient-centered care.
Longitudinal monitoring reveals that persistence and growth dynamics of peripheral globules in melanocytic lesions predict melanoma risk more accurately than static features alone, informing tailored surveillance strategies.
The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.
A Phase II trial assessed the combination of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type ovarian granulosa cell tumor, showing limited objective response but clinically meaningful progression-free survival witho
This national NHS cohort study evaluates how adherence to colonoscopy surveillance affects colorectal cancer incidence and mortality among Lynch syndrome patients, revealing decreased mortality despite unchanged incidence, raising implicati
The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome
Genomic alterations in primary gastric tumors, including KRAS and PIK3CA mutations, correlate with recurrence risk and metastatic patterns, informing personalized postoperative surveillance and treatment strategies.
This study identifies that 30% of gynecologic cancer clinical trials fail to complete, with insufficient patient accrual as the leading cause, highlighting crucial factors like intervention type, initiation year, and geographic variations t
BEACON-HCC is a multidisciplinary, evidence-based North American consensus that updates HCC treatment allocation—integrating tumor biology, nuanced intrahepatic burden, vascular invasion, and newer modalities (EBRT, TARE, systemic–locoregio
Open language-specific specialty feeds and department pages.